Cargando…

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

BACKGROUND: To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal cancer mCRC randomized onto the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passardi, Alessandro, Scarpi, Emanuela, Cavanna, Luigi, Dall'Agata, Monia, Tassinari, Davide, Leo, Silvana, Bernardini, Ilaria, Gelsomino, Fabio, Tamberi, Stefano, Brandes, Alba A., Tenti, Elena, Vespignani, Roberto, Frassineti, Giovanni L., Amadori, Dino, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078087/ https://www.ncbi.nlm.nih.gov/pubmed/27120807 http://dx.doi.org/10.18632/oncotarget.8901

Ejemplares similares

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2015)

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2018)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Prognostication in palliative radiotherapy—ProPaRT: Accuracy of prognostic scores
por: Maltoni, Marco, et al.
Publicado: (2022)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes
por: Pallotti, Maria Caterina, et al.
Publicado: (2021)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Non-Kahler attracting manifolds
por: Dall'Agata, Gianguido
Publicado: (2006)

Special Issue on Basic and Translational Research in Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Molecular and Translational Research on Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2020)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
por: Passardi, Alessandro, et al.
Publicado: (2021)

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors
por: Passardi, Alessandro, et al.
Publicado: (2023)

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
por: Capelli, Laura, et al.
Publicado: (2016)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
por: Rocca, Andrea, et al.
Publicado: (2021)

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease
por: Casadei Gardini, Andrea, et al.
Publicado: (2013)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
por: Ulivi, Paola, et al.
Publicado: (2013)

On sgoldstino-less supergravity models of inflation
por: Dall'Agata, Gianguido, et al.
Publicado: (2014)

Flow equations and attractors for black holes in N = 2 U(1) gauged supergravity
por: Dall'Agata, Gianguido, et al.
Publicado: (2010)

Gauged supergravity algebras from twisted tori compactifications with fluxes
por: Dall'Agata, Gianguido, et al.
Publicado: (2005)

Updates in local supersymmetry and its spontaneous breaking
por: Dall'Agata, Gianguido, et al.
Publicado: (2006)

Scherk-Schwarz reduction of M-theory on G2-manifolds with fluxes
por: Dall'Agata, G, et al.
Publicado: (2005)

Worldsheet theories for non-geometric string backgrounds
por: Dall'Agata, Gianguido, et al.
Publicado: (2008)

The challenge of sustainability in healthcare systems: frequency and cost of diagnostic procedures in end-of-life cancer patients
por: Massa, Ilaria, et al.
Publicado: (2018)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy
por: Brandes, Alba A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cojij32euvfhbhtapjeosg0nvg